Literature DB >> 26879099

Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.

Roberto Minutolo1, Maurizio Borzumati2, Stefano Sposini3, Cataldo Abaterusso4, Gianni Carraro5, Alberto Santoboni6, Carlo Mura7, Oliviero Filiberti8, Domenico Santoro9, Romano Musacchio10, Patrizio Imperiali11, Fulvio Fiorini12, Luca De Nicola13, Domenico Russo14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26879099     DOI： 10.1053/j.ajkd.2016.01.011

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  7 in total

1.  Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.

Authors:  Ravi Thadhani; Ruffy Guilatco; Jeffrey Hymes; Franklin W Maddux; Ajay Ahuja
Journal:  Am J Nephrol       Date:  2018-09-07       Impact factor: 3.754

2.  Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.

Authors:  Carla Rognoni; Vittorio Ortalda; Caterina Biasi; Giovanni Gambaro
Journal:  Adv Ther       Date:  2019-09-05       Impact factor: 3.845

3.  Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

Authors:  Valeria Belleudi; Francesco Trotta; Antonio Addis; Ylenia Ingrasciotta; Valentina Ientile; Michele Tari; Rosa Gini; Maurizio Pastorello; Salvatore Scondotto; Pasquale Cananzi; Giuseppe Traversa; Marina Davoli; Gianluca Trifirò
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

4.  Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.

Authors:  Yifei Liu; Min Yang; Vishvas Garg; Eric Q Wu; Jessie Wang; Martha Skup
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

5.  Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.

Authors:  Ylenia Ingrasciotta; Francesco Giorgianni; Ilaria Marcianò; Jenny Bolcato; Roberta Pirolo; Alessandro Chinellato; Valentina Ientile; Domenico Santoro; Armando A Genazzani; Angela Alibrandi; Andrea Fontana; Achille P Caputi; Gianluca Trifirò
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

Review 6.  Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.

Authors:  Matti Aapro; Andriy Krendyukov; Martin Schiestl; Pere Gascón
Journal:  BioDrugs       Date:  2018-04       Impact factor: 5.807

Review 7.  Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.

Authors:  Ross A McKinnon; Matthew Cook; Winston Liauw; Mona Marabani; Ian C Marschner; Nicolle H Packer; Johannes B Prins
Journal:  BioDrugs       Date:  2018-02       Impact factor: 5.807
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.